Plain-English translation of NCT07101432 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called TROP2 CAR/IL-15 TGFBR2 KO NK cells—immune cells that are grown in the lab, specially engineered to fight cancer, and given back to patients. Some participants will also receive radiation therapy before receiving the cells. The main goal is to learn whether this treatment is safe and whether it can help shrink tumors in people whose head and neck cancer has stopped responding to other treatments.
Advanced head and neck cancer that comes back or keeps growing after standard treatments is very difficult to treat, and patients need new options. This medication uses the body's own immune system in a new way to target cancer cells, and researchers want to understand if combining it with radiation makes it work better.
You likely qualify if…
You likely don't qualify if…
Participants come to the hospital as outpatients to receive the treatment. First, you will receive chemotherapy to prepare your body for the new immune cells (called lymphodepleting chemotherapy). Some participants will also receive radiation therapy to one or more tumor sites. Then you will receive an infusion of the engineered immune cells. Your medical team will monitor you closely with blood tests, imaging scans, and physical exams to watch for side effects and to see how well the treatment is working.
AI-generated summary from trial data · Aug 25, 2026 · Not medical advice
United States